IMRX Immuneering Corp

USD 1.80 0.03 1.694915
Icon

Immuneering Corp (IMRX) Stock Analysis and Price Targets

COMMON STOCK | Biotechnology | NSD
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

Sell

Average User
Rating

USD 1.80

+0.03 (+1.69)%

USD 0.08B

0.52M

USD 13.67(+659.26%)

USD 24.00 (+1233.33%)

Icon

IMRX

Immuneering Corp (USD)
COMMON STOCK | NSD
USD 1.80
0.00 0
Take a Tour
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

Sell

Average User
Rating

USD 0.08B

USD 24.00 (+1233.33%)

USD 1.80

Immuneering Corp (IMRX) Stock Forecast

Show ratings and price targets of :
USD 13.67
(+659.26%)

Based on the Immuneering Corp stock forecast from 4 analysts, the average analyst target price for Immuneering Corp is USD 13.67 over the next 12 months. Immuneering Corp’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Immuneering Corp is Bearish, which is based on 1 positive signals and 5 negative signals. At the last closing, Immuneering Corp’s stock price was USD 1.80. Immuneering Corp’s stock price has changed by -14.29% over the past week, -29.96% over the past month and -86.08% over the last year.

No recent analyst target price found for Immuneering Corp
No recent average analyst rating found for Immuneering Corp

Company Overview Immuneering Corp

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cance...Read More

https://immuneering.com

245 Main Street, Cambridge, MA, United States, 02142

68

December

USD

USA

Adjusted Closing Price for Immuneering Corp (IMRX)

Loading...

Unadjusted Closing Price for Immuneering Corp (IMRX)

Loading...

Share Trading Volume for Immuneering Corp Shares

Loading...

Compare Performance of Immuneering Corp Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for IMRX

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Immuneering Corp (Sector: Biotechnology )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX
Vertex Pharmaceuticals Inc +0.80 (+0.20%) USD107.38B 29.93 21.06

ETFs Containing IMRX

Symbol Name IMRX's Weight Expense Ratio Price(Change) Market Cap
no data

Frequently Asked Questions About Immuneering Corp (IMRX) Stock

Based on ratings from 4 analysts Immuneering Corp's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 5 buy, sell and 1 hold ratings.

Unfortunately we do not have enough data on IMRX's stock to indicate if its a good dividend stock.

Based on targets from 4 analysts, the average taret price for IMRX is USD 13.67 over the next 12 months. The maximum analyst target price is USD 20 while the minimum anlayst target price is USD 3.

Unfortunately we do not have enough data on IMRX's stock to indicate if its overvalued.

The last closing price of IMRX's stock was USD 1.80.

The most recent market capitalization for IMRX is USD 0.08B.

Based on targets from 4 analysts, the average taret price for IMRX is projected at USD 13.67 over the next 12 months. This means that IMRX's stock price may go up by +659.26% over the next 12 months.

We can't find any ETFs which contains Immuneering Corp's stock.

As per our most recent records Immuneering Corp has 68 Employees.

Immuneering Corp's registered address is 245 Main Street, Cambridge, MA, United States, 02142. You can get more information about it from Immuneering Corp's website at https://immuneering.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...